CoChat

Molecular mechanisms of corticosteroids in all_ergic diseases

Open access
Barnes, P. J. · 2001 · Allergy
Cited by 109

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Corticosteroids are by far the most effective therapy currently available for all_ergic diseases, such as asthma. We now have a much better understanding of the molecular mechanisms whereby corticosteroids suppress inflammation in all_ergic diseases. Corticosteroids are a highly effective anti-inflammatory therapy in all_ergy, and the molecular mechanisms involved in the suppression of all_ergic inflammation are now better understood (1). Corticosteroids are effective clinicall_y because they block many of the inflammatory pathways that are abnormall_y activated in all_ergic diseases, and they have a very wide spectrum of anti-inflammatory actions. Corticosteroids bind to a single class of glucocorticoid receptor (GR) that is localized to the cytoplasm of target cells. Corticosteroids bind at the C-terminal end of the receptor, whereas the N-terminal end of the receptor is involved in gene transcription. Between these domains is the DNA-binding domain, which has two finger-like projections, formed by a zinc molecule bound to four cysteine residues, that bind to the DNA double helix. The inactive GR is bound to a protein complex that includes two molecules of the 90-kDa heat-shock protein (hsp90) and various other proteins that act as "molecular chaperones" to prevent the unoccupied GR from moving into the nuclear compartment. Once corticosteroids bind to GR, conformational changes in the receptor structure result in dissociation of these chaperone molecules, thereby exposing nuclear localization signals on GR, and resulting in rapid nuclear localization of the activated GR-corticosteroid complex and its binding to DNA (Fig. 1). Two GR molecules bind to DNA as a dimer, resulting in changed transcription. A splice variant of GR, termed GR-β, has been identified that does not bind corticosteroids, but does bind to DNA, and theoreticall_y may interfere with the action of corticosteroids by blocking GRE binding (2). Classical model of corticosteroid action. Corticosteroids enter the cell and bind to cytoplasmic glucocorticoid receptors (GR) that are complexed with two molecules of a 90-kDa heat-shock protein (hsp90). GR translocates to the nucleus, where, as a dimer, it binds to a glucocorticoid recognition element (GRE) on the 5′-upstream promoter sequence of steroid-responsive genes. GREs increase transcription, whereas negative GREs (nGREs) may decrease transcription, resulting in increased or decreased messenger RNA (mRNA) and protein synthesis. An isoform of GR, GR-β, binds to DNA but is not activated by corticosteroids. Corticosteroids produce their effect on responsive cells by activating GR to regulate directly or indirectly the transcription of certain target genes (3). The number of genes per cell directly regulated by corticosteroids is estimated to be between 10 and 100, but many genes are indirectly regulated through an interaction with other transcription factors. GR dimers bind to DNA at consensus sites termed "glucocorticoid response elements" (GREs) in the 5′-upstream promoter region of steroid-responsive genes. This interaction changes the rate of transcription, resulting in either induction or repression of the gene. Interaction of the activated GR homodimer with GRE usuall_y increases transcription, resulting in increased protein synthesis. GR may increase transcription by interacting with a large coactivator molecule, CREB-binding protein (CBP). CBP is bound at the start site of transcription, and this leads via a series of linking proteins to the binding and activation of RNA polymerase II, resulting in the formation of messenger RNA (mRNA) and then synthesis of protein. Binding of activated GR to CBP results in increased acetylation of core histones around which DNA is wound within the chromosomal structure (4), and this is critical for the subsequent activation of RNA polymerase II. For example, high concentrations of corticosteroids increase the secretion of the antiprotease secretory leukoprotease inhibitor (SLPI) from epithelial cells. This is associated with a selective acetylation of lysine residues 5 and 16 on histone 4, resulting in increased gene transcription. In controlling inflammation, the major effect of corticosteroids is to inhibit the synthesis of inflammatory proteins. This was originall_y believed to be through the interaction of GR with negative GREs, resulting in repression of transcription. However, negative GREs have only very rarely been demonstrated and are not a feature of the promoter region of inflammatory genes that are suppressed by steroids in the treatment of all_ergic diseases. Activated GRs may bind directly to several other activated transcription factors as a protein–protein interaction. This could be an important determinant of corticosteroid responsiveness, and it is a key mechanism whereby corticosteroids switch off inflammatory genes. Most of the inflammatory genes that are activated in asthma do not appear to have GREs in their promoter regions, and

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1034/j.1398-9995.2001.00001.x

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 109

Metadata

Authors
Barnes, P. J.
Venue
Allergy
Publisher
Wiley
Published
2001-10
Volume
56
Issue
10
Pages
928-936
ISSN
  • 0105-4538 (ISSN-L)
  • 1398-9995
OpenAlex
W1966159794
Cited by
109
References
4
FWCI
3.87
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular mechanisms of corticosteroids in all_ergic diseases. https://app.cochat.ai/papers/10.1034/j.1398-9995.2001.00001.x
The paper
Barnes, P. J. (2001). Molecular mechanisms of corticosteroids in all_ergic diseases. Allergy. https://doi.org/10.1034/j.1398-9995.2001.00001.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.